Preliminary Safety and Efficacy of Myeloablative Orca-Q in Patients with Haploidentical Donors

Key Points

• Myeloablative orca-q shows promising safety and efficacy outcomes in patients with haploidentical donors.
• Key evidence from a preliminary study indicates lower adverse events compared to traditional methods.
• The analysis involved a cohort receiving orca-q in a medical setting, assessing transplant success and sustainability.
• These findings highlight the need for further validation in larger trials to establish broader applicability.